ACTH 1-17 effects on intermediary metabolites in healthy subjects.
Some acute and chronic metabolic effects of a new ACTH analogue (ACTH 1-17, Synchrodyn) were evaluated in healthy subjects and compared to those of the synthetic fragment ACTH 1-24. The peptides were injected at doses reportedly comparable with regard to their corticotropic effect, i.e. 100 micrograms ACTH 1-17 and 250 micrograms ACTH 1-24. A similar increase in blood glucose, NEFA and ketone bodies concentrations, without any significant modification of insulin, C-peptide and glucagon levels, was observed after injecting both peptides. The chronic treatment with ACTH 1-24 induced a significant increase in basal lactate, pyruvate and alanine blood concentrations. The levels of these metabolites resulted unaffected or slightly reduced after the corresponding treatment with ACTH 1-17. Our data are compatible with a certain degree of exhaustion of the adrenocortical reserve or, alternatively, a resetting of the circadian cortisol rhythm after prolonged treatment with the ACTH 1-17 analogue.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000409:Alanine / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005934:Glucagon / Q000097:blood; D005990:Glycerol / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007657:Ketone Bodies / Q000097:blood; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D008660:Metabolism / Q000187:drug effects*; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology*; D011773:Pyruvates / Q000097:blood; D019289:Pyruvic Acid; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D007328:Insulin; D007657:Ketone Bodies; D007773:Lactates; D010446:Peptide Fragments; D011773:Pyruvates; D019344:Lactic Acid; D019289:Pyruvic Acid; D000324:Adrenocorticotropic Hormone; D005934:Glucagon; C028238:ACTH (1-17); D000409:Alanine; D005990:Glycerol